VOLITIONRX LTD — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
VolitionRx filed an 8-K on September 2, 2026 (period ending August 27, 2026) disclosing an unregistered sale of equity securities under Item 3.02. The filing document does not provide specific details on counterparties, dollar amounts, share counts, prices, or terms of the sale.
Why this rating
Filing discloses equity issuance but lacks concrete terms; unregistered sales routine; insufficient data to assess dilution magnitude relative to ~$72.9M market cap.
Extracted items
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.